← Back to Search

EHR Alert System for Hemorrhagic Stroke

N/A

Recruiting

Led By Christopher D Anderson, MD MMSc

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients aged 18 years or older presenting with a primary diagnosis of hemorrhagic stroke admitted to Massachusetts General Hospital inpatient stroke service

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial aims to improve care of stroke survivors by alerting providers to common risk factors & comorbidities. A custom EHR module will test performance & effectiveness to intervene before any disparities arise.

Who is the study for?

This trial is for adults over 18 who have had a hemorrhagic stroke and are admitted to the Massachusetts General Hospital inpatient stroke service. It's not open to those with subdural or epidural hematoma, or anyone who doesn't fit the main inclusion criteria.Check my eligibility

What is being tested?

The study aims to see if alerting healthcare providers through electronic health records about risk factors and comorbidities can improve management of patients after a hemorrhagic stroke. The focus is on increasing checks for cholesterol (LDL) levels, blood sugar control (HbA1c), sleep apnea, and hearing issues.See study design

What are the potential side effects?

Since this trial involves using an electronic notification system rather than medication, there aren't direct side effects like you'd expect from drugs. However, there may be indirect impacts on patient care based on how providers respond to alerts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 or older and was admitted to Massachusetts General Hospital for a hemorrhagic stroke.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients with HbA1c measurements

Proportion of patients with LDL measurements

Secondary outcome measures

Proportion of patients with intensification of antidiabetic therapy

Proportion of patients with intensification of lipid-lowering therapy

Proportion of patients with management of hearing impairment

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Electronic Health Record NotificationExperimental Treatment1 Intervention

For eligible patients presenting with an acute hemorrhagic stroke, a recommendation to measure low-density lipoprotein (LDL) and glycated hemoglobin A1c (HbA1c) together with their last measurement dates will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the patient's provider when they first open the patient's chart. The provider may accept the automatically generated orders for both measurements displayed in the BPA, may modify one or both of the orders, or choose to dismiss the BPA. For patients that follow-up with the out-patient stroke clinic and received the in-patient intervention, a second BPA will suggest referrals to sleep study and audiology. The alert will display for the patient's provider when they first open the patient's chart. The provider may accept one or both of the referrals suggested by the BPA, or may choose to dismiss the BPA.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,935 Previous Clinical Trials

13,198,341 Total Patients Enrolled

2 Trials studying Hemorrhagic Stroke

1,500 Patients Enrolled for Hemorrhagic Stroke

Tufts UniversityOTHER

265 Previous Clinical Trials

661,603 Total Patients Enrolled

Boston UniversityOTHER

455 Previous Clinical Trials

9,941,325 Total Patients Enrolled

Media Library

In-patient and out-patient electronic health record alert Clinical Trial Eligibility Overview. Trial Name: NCT05643001 — N/A

Hemorrhagic Stroke Research Study Groups: Electronic Health Record Notification

Hemorrhagic Stroke Clinical Trial 2023: In-patient and out-patient electronic health record alert Highlights & Side Effects. Trial Name: NCT05643001 — N/A

In-patient and out-patient electronic health record alert 2023 Treatment Timeline for Medical Study. Trial Name: NCT05643001 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can individuals still register for this research endeavor?

"Based on the information found in clinicaltrials.gov, this experiment is not currently recruiting patients. The trial was first announced on December 1st 2022 and has recently been updated November 30th 2022. Despite there being no openings for individuals to join at this time, 991 other medical trials are actively looking for participants as of now."

Answered by AI

What is the primary purpose of this medical research study?

"This clinical trial, slated to last 12 months and monitored by our team, will be centrally focused on the proportion of patients whose HbA1c measurements have improved. We are also measuring secondary outcomes such as the proportion of patients who have attempted management for hearing impairment (e.g., audiology appointments), lipid-lowering therapy intensification (prescription or dose increase) and antidiabetic medication intensification (new prescription or dose alteration). All this data is based off electronic health records documentation during a 6 month follow up period after discharge from an acute hemorrhagic stroke."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke

Christopher D. Anderson, MD, MMSc 2023. "Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05643001.